QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

Rhea-AI Summary

QIAGEN (NYSE: QGEN) has announced the filing of its annual report on Form 20-F with the U.S. Securities and Exchange Commission, which includes audited consolidated financial statements for the fiscal year ended December 31, 2024. The report is accessible on QIAGEN's website, and the company will provide printed copies free of charge to shareholders upon request through their contact form or via email at ir@qiagen.com.

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.

QIAGEN will provide printed copies of the 2024 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2024 Annual Report please use our contact form or send an email to ir@qiagen.com.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the “Risk Factors” contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

Source: QIAGEN

Category: Corporate

View source version on businesswire.com: https://www.businesswire.com/news/home/20250330359265/en/

Contacts QIAGEN:

Investor Relations

John Gilardi, +49 2103 29 11711

Domenica Martorana, +49 2103 29 11244

e-mail: ir@QIAGEN.com

Public Relations

Thomas Theuringer, +49 2103 29 11826

Lisa Specht, +49 2103 29 14181

e-mail: pr@QIAGEN.com

Source: QIAGEN N.V.

FAQ

Where can investors access QIAGEN's 2024 Form 20-F annual report?

QIAGEN's 2024 Form 20-F annual report is available on the company's website and can be requested in print format through their contact form or by emailing ir@qiagen.com.

How can shareholders obtain a printed copy of QIAGEN's 2024 annual report?

Shareholders can request a free printed copy of QIAGEN's 2024 annual report through the company's contact form or by emailing ir@qiagen.com.

What period does QIAGEN's latest Form 20-F cover?

QIAGEN's Form 20-F covers the fiscal year ended December 31, 2024.

What stock exchanges is QIAGEN (QGEN) listed on?

QIAGEN is listed on the New York Stock Exchange (NYSE: QGEN) and Frankfurt Prime Standard (QIA).